The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • PharmAust subsidiary Epichem has announced Colin La Galia as its new CEO
  • Colin has over 20 years of experience in a senior role
  • At the same time, Dr Martine Keenan will resume her role as Epichem’s Head of Drug Discovery
  • Shares are up 4 per cent, trading for 13 cents apiece

PharmAust has announced that Colin La Galia has been appointed the new CEO of its subsidiary Epichem.

Colin has previously worked as the Regional Business Director and Commercial Head of Asia Pacific, China, and Japan for Abbott Rapid Diagnostics.

He has also held senior roles for over 20 years at Alera Inc, Origin Healthcare, Hollywood Fertility Centre, Merck Sharpe & Dohme, and GlaxoSmithKline.

Colin is highly experienced in pharmaceuticals, devices and diagnostics both locally and internationally, and has demonstrated success in international business development.

Executive Chairman Dr Roger Aston is pleased to have someone of Colin’s calibre join the team.

“We are all delighted that Colin has decided to join Epichem. He has an outstanding record in driving performance and adding value, and we are confident that Colin will be able to grow and diversify the Epichem business and take the business to the next level of increased revenues and profitability,” he said.

Simultaneously, Dr Martine Keenan will resume her former role as Epichem’s Head of Drug Discovery and will also join its board.

“Martine’s tenure as Epichem CEO has seen the revenues grow to the highest point in Epichem’s fifteen year history and we are delighted that she will be full time Head of Drug Discovery again and also be available to us on the Epichem Board,” Dr Roger said.

“The changes are a win all around for both Epichem and PharmAust,” he added.

PharmAust shares are up 4 per cent, with each one trading for 13 cents apiece.

PAA by the numbers
More From The Market Online
The Market Online Video

ASX Daily Close: ASX matches futures prediction on a green Friday | 21 June 2024

The ASX200 reversed its trend to end the week in the green, up 0.35%. Nearly all…
The Market Online Video

ASX Market Update: Stocks swing from green with energy to remorseful red | 21 June, 2024

The ASX200 came out the gate in the green on Friday, but slipped well below the red line within the first hour of

Week 25 Wrap: No RBA cut yet; India stocks shake off Modi jitters; China concerns remain

The RBA keeps rates on pause; Guzman Gomez falls nearly -5% on Friday; Droneshield's new ATH;…

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

The one defining feature of our post-COVID 'new normal' is a USA swing towards domestic supply…